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Objectives This study hypothesized that peak expiratory flow rate (PEFR) would increase with acute heart failure (AHF)
treatment over the first 24 h, related to a Dyspnea Index (DI) change and treatment effect.
Background Dyspnea is a key symptom and clinical trial endpoint in AHF, yet objective assessment is lacking.
Methods In a clinical trial substudy, 421 patients (37 sites) underwent PEFR testing at baseline, 1, 6, and 24 h after ran-
domization to nesiritide or placebo. DI (by Likert scale) was collected at hours 6 and 24.
Results Patients were median age 70 years, and 34% were female; no significant differences between nesiritide or
placebo patients existed. Median baseline PEFR was 225 l/min (interquartile range [IQR]: 160 to 300
l/min) and increased to 230 l/min (2.2% increase; IQR: 170 to 315 l/min) by hour 1, 250 l/min (11.1%
increase; IQR: 180 to 340 l/min) by hour 6, and 273 l/min (21.3% increase; IQR: 200 to 360 l/min) by
24 h (all p  0.001). The 24-h PEFR change related to moderate or marked dyspnea improvement by DI
(adjusted odds ratio: 1.04 for each 10 l/min improvement [95% confidence interval (CI): 1.07 to 1.10]; p 
0.01). A model incorporating time and treatment over 24 h showed greater PEFR improvement after nesirit-
ide compared with placebo (p  0.048).
Conclusions PEFR increases over the first 24 h in AHF and could serve as an AHF endpoint. Nesiritide had a greater effect
than placebo on PEFR, and this predicted patients with moderate/marked improvement in dyspnea, thereby pro-
viding an objective metric for assessing AHF. (Acute Study of Clinical Effectiveness of Nesiritide in Decompen-
sated Heart Failure [ASCEND-HF]; NCT00475852) (J Am Coll Cardiol 2012;59:1441–8) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.061Shortness of breath is 1 of the principal presenting symp-
toms of patients with acute decompensated heart failure
(AHF) (1), and relief of this dyspnea is a commonly
employed endpoint for clinical care and randomized clinical
trials of AHF therapy (2). Yet assessment of dyspnea is
subjective, difficult to validate, and the relationship to
objective measures is unknown (1,3,4). Despite this short-
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given the importance assigned to this symptom (5–7).
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Peak Expiratory Flow Rate in AHF April 17, 2012:1441–8Whereas a recent study enrolling
patients with AHF very early in
the emergency department re-
ported that patient-assessed vi-
sual analogue and Likert scales
evaluating the change in dyspnea
were highly correlated, these re-
sults differed when provocative
orthopnea testing was intro-
duced. Hence, the relationship
between dyspnea and more objective
measures remains unclear (1).
Although the mechanisms of
dyspnea are multiple, bronchoc-
onstriction is thought to be a key
modulator (8). Peak expiratory
flow rate (PEFR) is a measure
that reflects airflow limitation
and is primarily determined by
large airway caliber, expiratory muscle strength, elastic
recoil, and resistance of the smaller intrathoracic airways (9).
Because PEFR is inexpensive, portable, and widely used for
the assessment of asthma and chronic obstructive lung
disease, it is frequently used as an endpoint in clinical trials of
asthma control (10).
Three studies have evaluated the use of PEFR for the
diagnosis of patients with AHF (11–13). All found that
patients with AHF could be readily distinguished from
those with chronic lung disease by PEFR; however, its value
for the diagnosis of heart failure (HF) is limited. However,
only baseline PEFR measures were used in these mixed
cardiovascular and respiratory disease populations with the
goal of demonstrating diagnostic utility, rather than poten-
tial as an objective clinical trial endpoint. To date, no studies
to our knowledge have described change in PEFR from
baseline over time in patients with AHF.
We evaluated the baseline and sequential change in
PEFR over the first 24 h from admission in a prospective
substudy of the ASCEND-HF (Acute Study of Clinical
Effectiveness of Nesiritide in Decompensated Heart Fail-
ure), a large trial of patients with AHF. Additionally, we
examined the relationship of PEFR to clinical outcomes,
and the effect of nesiritide or placebo on PEFR. Finally, we
explored the relationship of a subjective Dyspnea Index (DI)
to PEFR.
Methods
Study design. The study design and results of the
ASCEND-HF study have been previously published (2,5).
Briefly, the ASCEND-HF study evaluated nesiritide versus
placebo in 7,007 patients with AHF enrolled within 24 h of
first intravenous HF–related treatment. Participants were
required to have each of the following at time of random-
ization: dyspnea at rest or with minimal activity; 1
Abbreviations
and Acronyms
AHF  acute
decompensated heart
failure
BNP  B-type natriuretic
peptide
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
DI  Dyspnea Index
FEV1  forced expiratory
volume in 1 s
HF  heart failure
PEFR  peak expiratory
flow rateaccompanying sign (respiratory rate 20 breaths/min orpulmonary congestion/edema with rales 1/3 base); and
1 objective measure of HF (evidence of congestion/edema
on chest x-ray; B-type natriuretic peptide [BNP] 400
g/ml or N-terminal pro-BNP 1,000 pg/ml; pulmonary
apillary wedge pressure 20 mm Hg; or left ventricular
jection fraction 40% in the previous 12 months). Among
thers, 1 exclusion criteria germane to this substudy was
evere pulmonary disease (full exclusion criteria are available
lsewhere) (5).
espiratory substudy design. Patients in the prospectively
planned respiratory substudy were enrolled between May
2007 and August 2010 at 37 sites in Canada and the United
States. Consecutive patients were approached for enroll-
ment at the time of entry into the main trial. The institu-
tional review board at each participating hospital approved
the protocol, and patients were required to provide written
informed consent. The study team at each site completed
standardized training including how to perform PEFR, and
the same type of PEFR meter was used across all sites along
with standardized patient and study team instructions.
PEFR, that is, the maximal flow generated on expiration
after full inspiration, was performed at baseline (after
randomization, but before drug infusion) and at 1 h, 6 h,
and 24 h thereafter. Three measurements were completed at
each time point, with the highest PEFR recorded in l/min
(11–13). Other data captured simultaneously included re-
spiratory rate in breaths/min, oxygen saturation (%), and
liters of oxygen delivered (in l/min).
Sample sizes were estimated from 3 prior studies of
dyspneic patients with cardiovascular disease that showed
baseline PEFRs of 224 l/min (SD: 82 l/min) (12), 253 l/min
(SD: 93 l/min) (13), and 267 l/min (SD: 97 l/min) (11), and
1 study of patients with an acute exacerbation of chronic
obstructive pulmonary disease (COPD), which had a mean
PEFR of 113 l/min (SD: 51 l/min) (14). An improvement
in the PEFR between 10 to 25 l/min, or approximately 5%
to 12%, was considered clinically significant based on
asthma studies (15,16). We assumed that with a baseline
mean PEFR of 200 l/min (SD: 80 l/min), 200 patients per
treatment arm would provide 80% power to detect a
clinically meaningful 20% change (between nesiritide and
placebo groups) in PEFR with a p value 0.05. A total of
400 patients would also result in adequate measurements to
ascertain the time course of change, detect any differences
between groups, and allow for drop-outs and missing data
of 10% of PEFR measurements.
Statistical analysis. Data for continuous variables are pre-
sented as medians with 25th and 75th percentiles, and
categorical variables are presented as frequencies and per-
centages. Wilcoxon rank sum tests were used to measure
differences for continuous variables, and the chi-square test
was used for categorical variables. Differences in continuous
variables over time followed a Gaussian distribution and are
reported as means with confidence intervals (CI) using
t tests for comparison. Adjustment for baseline differences
was done using covariate adjustment. Repeated-measures
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April 17, 2012:1441–8 Peak Expiratory Flow Rate in AHFanalysis of covariance was used to model the effects of
treatment group and to control for baseline PEFR. The
groups were defined by the intention-to-treat groups as per
the main trial protocol for the principal analysis. An
additional “on-treatment” group was used to evaluate effects
of patients receiving study drug or placebo as a sensitivity
analysis. Outliers were examined for PEFR using the
methods of Shiffler (17). Log transformation was used to
normalize the PEFR data for evaluation. A correlation
analysis was used to evaluate the association of the DI score
and the change in PEFR. Additionally, a series of parsimo-
nious logistic regression models were developed for predict-
ing both significant improvement in dyspnea score, and for
the composite outcome of HF rehospitalization or death at
30 days. Candidate variables included age, sex, PEFR, and
treatment assignment. A p value of 0.05 was used as the
level of statistical significance for all tests. A statistical
analysis plan was developed before data analysis; all analyses
were pre-specified unless otherwise stated. All analyses were
performed using R Software (version 2.12.2, R Foundation
for Statistical Computing, Vienna, Austria).
Results
There were 430 patients enrolled in the respiratory sub-
study. PEFR data was available for 421, 406, 405, and 410
patients at baseline, hour 1, hour 6, and hour 24, respec-
tively. The 9 patients without baseline PEFR data were
excluded from further analyses. Of the 421 patients, 208
(49.4%) were in the nesiritide arm, and 213 (50.6%) in the
placebo arm. Comparisons with the 7,007 patients in the
overall trial as well as all the 2,728 ASCEND patients
enrolled in Canada or the United States are shown in Table 1.
As compared with patients from Canada or the United
States not in the respiratory substudy, those in the respira-
tory substudy were older, weighed less, and had higher
respiratory rates; however, measurements of BNP, N-terminal
pro–BNP, creatinine, and ejection fraction were similar.
Differences between patients in the nesiritide or placebo
arms are shown in Table 1. Small differences between
roups in the percent of patients on beta-blockers or
reatinine clearance were not associated with PEFR (p 
0.7 and p  0.4, respectively).
Peak expiratory flow rate. As shown in Table 2, Overall,
edian PEFR increased from 225 l/min (interquartile range
IQR]: 160 to 300 l/min) at baseline, to 230 l/min (IQR:
70 to 315 l/min) at hour 1, 250 l/min (IQR: 180 to 340
/min) at hour 6, and 273 l/min (21% increase, IQR: 200 to
60 l/min) at hour 24 (Table 2). Compared with baseline,
EFR increased by hour 1 (per patient average: 8.39 l/min;
5% CI: 2.89 to 13.89), hour 6 (26.32 l/min; 95% CI: 19.09
o 33.61), and at 24 h (43.92 l/min; 95% CI: 36.39 to
1.47).
espiratory rate and oxygen saturation. Median respira-
ory rate was 23.0 breaths/min at baseline and similar
etween the nesiritide and placebo groups (22 [IQR: 20 to4] vs. 23 [IQR: 21 to 24]; p  0.30). Respiratory rate
eclined per patient by 2.9 breaths/min (95% CI: 2.56 to
.22) over the first 24 h in the overall group from a median
f 23.0 (IQR: 21 to 24) to 20 (IQR: 18 to 22; p  0.0001).
Median oxygen saturation was 96% (IQR: 95% to 98%)
t baseline and remained similar over the next 24 h to a
edian of 97% (IQR: 95% to 98%); the mean per patient
ifference was 0.08% (95% CI: 0.19 to 0.34). Initially,
atients were on a median of 2 l/min of oxygen (IQR: 0 to
.8 l/min), which declined to a median of 0 l/min by 24 h;
he mean per patient decrease was 0.36 l/min (95% CI: 0.20
o 0.53). The difference was similar between the nesiritide
nd placebo groups.
esiritide versus placebo. The change in PEFR from
aseline to 24 h between the nesiritide and placebo arms was
tatistically significant, with greater improvement in the
esiritide arm compared with placebo (unadjusted mean
ifference: 52.4 l/min vs. 35.9 l/min; 95% CI of differ-
nce: 1.37 to 31.54; p  0.05). Individual pairwise compar-
sons at each time point did not show any significant
ifference between nesiritide and placebo. However, a re-
eated measures model incorporating time and treatment
roup showed a significant result favoring an improvement
n nesiritide versus placebo (p  0.05) (Fig. 1) for the
mprovement in PEFR.
Respiratory rate tended to decline more following nesirit-
de treatment as compared with placebo, that is, nesiritide
atients had an additional 0.67 breaths/min reduction at
4 h (p  0.07) not evident earlier at baseline, 1 h, or 6 h.
here were no significant differences between the nesiritide
nd placebo groups in either oxygen saturation or delivered
xygen over the 24 h.
I and PEFR. Baseline PEFR was unrelated to the 6-h or
4-h DI result (rho0.017, p 0.73; rho0.08, p
.11, respectively). Additionally, the change in PEFR from
aseline to 6 h did not correlate with the simultaneous DI
easurement at 6 h (rho  0.03, p  0.5). At 24 h, the DI
howed a small but significant correlation with change in
EFR from baseline to 24 h (rho  0.15, p  0.002).
The relationship between PEFR and DI at 24 h was
urther explored to evaluate whether the improvement in
EFR predicted patients with a moderate or markedly
mproved response on the DI. The regression model at 24 h
hows a significant relationship: an increased PEFR pre-
icted improved DI at 24 h (C-index: 0.60; odds ratio: 1.04
or each 10 l/min improvement [95% CI: 1.01 to 1.07]; p
.01). Figure 2 shows the relationship divided into 2 groups:
patients with an improvement in DI (n  272) and those
without improvement (n  127) demonstrating an improv-
ing PEFR over time by group.
No relationship was seen between the change in DI and
change in respiratory rate (i.e., the change in respiratory rate
by 24 h was unrelated to the DI response at 24 h).
Clinical outcomes. Similar to the overall study, the 30-day
mortality and HF re-hospitalization rate in the substudy
was 2.8% (n  12 events) and 10.0% (n  43 events),
Baseline Characteristics of Patients in Overall Trial, North America, and Respiratory SubstudyTable 1 Baseline Characteristics of Patients in Overall Trial, North America, and Respiratory Substudy
Variable
Overall Trial
(N  7,007)
North America Substudy
Not Enrolled in Substudy
(n  2,728)
Enrolled in Substudy
(n  421) p Value
Nesiritide
(n  208)
Placebo
(n  213) p Value
Demographics
Age, yrs 67 (56–76) 67 (56–78) 70 (59–79) 0.003 69 (58–80) 70 (59–79) 0.72
Female 34.1 34.9 34.2 0.83 34.1 34.3 1.00
Race 0.001 0.52
White 55.9 64.0 68.2 65.9 70.4
Black 14.8 33.0 24.9 25.5 24.4
Asian 24.9 1.3 3.3 4.3 2.4
Other 4.3 1.7 3.6 4.3 2.8
Medical history
Heart failure admission 1 yr before admission 38.9 46.1 42.3 0.16 42.8 41.8 0.84
Prior myocardial infarction 34.9 34.6 39.0 0.09 38.0 39.9 0.69
Ischemic etiology for HF 47.9 43.6 42.0 0.56 40.9 43.2 0.69
Hypertension 72.2 81.5 79.1 0.26 81.7 76.5 0.23
Atrial fibrillation or flutter 37.5 41.7 46.1 0.09 43.8 48.4 0.38
Diabetes mellitus 42.6 49.6 44.7 0.07 42.3 47.0 0.34
Chronic respiratory disease 16.4 25.3 21.4 0.09 20.3 22.5 0.64
Measurements
Weight, kg 78 (64, 95) 88 (73, 106) 84 (73, 102) 0.03 84 (74, 101) 85 (72, 103) 0.97
Blood pressure, mm Hg
Systolic 123 (110, 140) 124 (111, 141) 123 (110, 137) 0.08 125 (110, 138) 121 (110, 137) 0.61
Diastolic 74 (67, 83) 72 (64, 83) 71 (62, 84) 0.31 72 (62, 85) 71 (63, 84) 0.94
Heart rate, beats/min 82 (72, 95) 80 (70, 90) 78 (68, 91) 0.30 77 (68, 91) 79 (68, 91) 0.96
Respiratory rate, breaths/min 23 (21, 26) 22 (20, 24) 24 (20, 24) 0.001 23 (20, 24) 24 (20, 25) 0.57
BNP, pg/ml 992 (548, 1879) 1,030 (603, 1,900) 1,106 (577, 1,914) 0.99 1,108 (633, 1,941) 1,040 (551, 1,914) 0.37
NT-proBNP 4,463 (2,108, 9,048) 4,799 (2,266, 9,331) 4,662 (2,707, 9,312) 0.90 4,268 (2,414, 9,509) 5,161 (2,967, 9,048) 0.54
Creatinine, mol/l 108 (88, 141) 115 (92, 150) 115 (88, 150) 0.29 108 (88, 141) 120 (88, 155) 0.02
BUN/urea, mg/dl 9.0 (6.4, 13.8) 8.6 (6.1, 12.1) 8.2 (5.8, 12.3) 0.24 7.5 (5.4, 11.1) 9.0 (6.2, 13.6) 0.001
Hemoglobin, g/dl 12.7 (11.3, 14) 12.3 (11, 13.7) 12.5 (11.1, 13.6) 0.46 12.4 (11.2, 13.6) 12.5 (11, 13.7) 0.68
LVEF* 0.38 0.26
40% 79 71 74 77 71
40% 21 29 26 23 29
Medical or device therapy
ACE inhibitor or ARB 61 62 65 0.23 64 67 0.61
Beta-blocker 58 74 70 0.07 65 75 0.03
Aldosterone blocker 28 24 18 0.02 18 19 0.80
Nitrates (oral or topical) 24 25 25 1.00 26 24 0.57
Loop diuretic 95.1 97.9 96.9 0.22 96.2 97.7 0.37
Implantable cardioverter-defibrillator 8.5 17.5 10.9 0.001 12.0 9.9 0.53
Biventricular pacemaker 1.3 1.7 2.1 0.55 1.0 3.3 0.18
Continued on next page
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April 17, 2012:1441–8 Peak Expiratory Flow Rate in AHFrespectively, with the composite rate of 12.1% (n  52
events) (5). Using a logistic regression model incorporating
4 variables (age, sex, treatment assignment, and PEFR), the
effect of baseline PEFR (and change from baseline to 24 h
in PEFR) on the 30-day composite outcome was evaluated.
Each 10 l/min increase in baseline PEFR was associated
with an adjusted odds ratio of 0.96 (95% CI: 0.92 to 0.98,
p  0.01), and the change from baseline to 24 h in PEFR
was similar but nonsignificant (odds ratio: 0.95 for 10 l/min
change over 24 h, 95% CI: 0.92 to 1.01; p  0.1).
Other analyses. There was no effect of bolus (vs. no bolus)
nesiritide use, baseline beta-blocker or other medication use,
or other baseline characteristics (including chronic respira-
tory disease) on PEFR. Additionally, there was no effect on
the overall results when time from presentation to the
emergency department to enrollment in the trial was incor-
porated into the multivariable model.
Discussion
This prospective substudy in AHF provides 3 novel obser-
vations: 1) PEFR shows a similar, clinically important
pattern of improvement within 24 h of admission, analo-
gous to that seen in acute respiratory diseases such as asthma
or exacerbations in COPD; 2) changes in PEFR over 24 h
predicted those AHF patients with a significant (moderately
or markedly) improvement in their subjective DI; and
3) changes in PEFR demonstrated a small difference in
respiratory function between nesiritide and placebo.
The minimal clinically important difference was postu-
lated by Jaeschke et al. (18) to help place statistical differ-
ences in clinical context. In patients with asthma, the
minimal clinically important difference for a PEFR has been
proposed to be an absolute value of 18 l/min (16) or a 12%
increase over baseline value (15), and for COPD trials,
between 10 to 32 l/min (19–21). Hence, our observation of
a mean increase of 44 l/min over 24 h falls well within this
range and thus appears to reliably demonstrate an objective
difference. Further studies will be required to establish
whether the minimal clinically important difference in AHF
should be expected to be greater, given the placebo group,
on top of background medical therapy that included diuret-
ics, also had an improvement in both PEFR and dyspnea.
Additionally, PEFR should be examined over a longer
duration of time (e.g., 5 days after admission) to see whether
these findings correlate with other clinical improvements.
There are a number of potential mechanisms by which
dyspnea may improve in patients with AHF with nesiritide,
and objective measurements such as PEFR improvement
may reflect 1 or more possibilities. For example, infusion of
nesiritide to stable outpatients with asthma has been shown
to increase forced expiratory volume in 1 s (FEV1) and
orced vital capacity by 36% and 24%, respectively, indicat-
ng a significant direct bronchodilator effect of nesiritide
22). Intravenous and inhaled atrial natriuretic peptide haveboth been shown to improve FEV1 in patients with asthmaC
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Peak Expiratory Flow Rate in AHF April 17, 2012:1441–8(23,24). The significant 18 l/min PEFR improvement with
nesiritide in our study is consistent with the impact of
nesiritide in these studies, albeit in a different population,
and should be put in context of the overall ASCEND-HF
trial result. The overall mechanism of how nesiritide and
other current therapies affect peak flow limitation and
dyspnea improvement is poorly understood.
The measurement of the symptom of dyspnea is clinically
important in AHF as it constitutes a treatment goal that is
subjectively assessed by both clinician and patient on a
day-to-day basis. Dyspnea is complex and has been defined
as “a subjective experience of breathing discomfort that
consists of qualitatively distinct sensations that vary in
intensity. . .derived from interactions among multiple phys-
iological, psychological, social, and environmental factors”
(8). Within clinical trials, dyspnea has been challenging to
Respiratory MeasurementsTable 2 Respiratory Measurements
Variable Patient Group Baseline
Respiratory rate, breaths/min All 22.5 (20, 24)
All 23.2 (22.8–23
Placebo 23.4 (22.7–23
Nesiritide 23.0 (22.5–23
Oxygen saturation, % All 96 (95, 98)
All 96.1 (95.9–96
Placebo 96.0 (95.7–96
Nesiritide 96.2 (95.8–96
Oxygen delivered, l/min All 2 (0, 2.5)
All 1.6 (1.4–1.8)
Placebo 1.4 (1.1–1.7)
Nesiritide 1.8 (1.5–2.1)
Peak expiratory flow rate, l/min All 225 (160, 30
All* 221 (211–23
Placebo* 224 (210–23
Nesiritide* 219 (206–23
Values are median (interquartile range) or mean (95% confidence interval). *Means and 95% con
Figure 1 Change in PEFR Over Time
With Nesiritide and Placebo
Error bars indicate 95% confidence intervals. PEFR  peak expiratory flow rate.measure as evident from the use of multiple different
dyspnea instruments seeking to internally “validate” a spe-
cific scale without external validation of the mechanisms,
psychometric properties, or objective measurement of dys-
pnea. Given the absence of a gold standard, clinical trials
have frequently used simple 5- or 7-point Likert scales
without further validation (25). Our findings, albeit only
when predicting improvement (as few subjects worsened),
demonstrate an objective correlate for the subjective mea-
sure of the 7-point DI.
Assessment of “soft” endpoints such as symptomatic
changes used in clinical trials of AHF therapy are difficult to
evaluate and deserve careful scrutiny. Until recently, the DI
(as assessed by visual analogue scale or Likert scale) had yet
Hour 1 Hour 6 Hour 24
22 (20, 24) 20 (18, 22) 20 (18, 22)
21.9 (21.6–22.3) 20.9 (20.5–21.2) 20.3 (20.0–20.7)
21.9 (21.4–22.3) 20.8 (20.3–21.2) 20.7 (20.2–21.3)
22.0 (21.5–22.5) 20.9 (20.4–21.4) 20.0 (19.6–20.4)
96 (95, 98) 96 (95, 98) 97 (95, 98)
96.0 (95.8–96.3) 96.0(95.8–96.2) 96.2 (95.9–96.4)
96.0 (95.7–96.4) 96.1 (95.9–96.4) 96.4 (96.0–96.7)
96.0 (95.7–96.4) 95.8 (95.5–96.2) 95.9 (95.6–96.3)
2 (0, 2.5) 1.5 (0, 2) 0 (0, 2)
1.6 (1.4–1.8) 1.5 (1.3–1.7) 1.2 (1.0–1.4)
1.4 (1.1–1.6) 1.3 (1.0–1.6) 1.1 (0.8–1.4)
1.8 (1.5–2.1) 1.7 (1.4–2.0) 1.4 (1.1–1.7)
230 (170, 315) 250 (180, 340) 272.5 (200, 360)
228 (218–239) 244 (233–255) 263 (252–275)
226 (212–242) 244 (228–261) 260 (244–276)
231 (216–246) 243 (229–259) 267 (251–285)
intervals are back transformed from log.
Figure 2 Change in PEFR Over Time and 95% CI
(Values Back Transformed From Log)
Patients were divided into those with 24-h Dyspnea Index (DI) moderate or
marked improvement (DI improvement, n  272) versus those without improve-
ment (No DI improvement, n  127). *p  0.01. CI  confidence interval;
PEFR  peak expiratory flow rate..5)
.9)
.5)
.3)
.3)
.5)
0)
1)
8)
3)
c
i
a
m
o
o
a
d
c
i
b
s
l
c
o
e
e
A
i
o
p
w
d
s
C
P
fi
A
w
l
t
c
m
m
e
1447JACC Vol. 59, No. 16, 2012 Ezekowitz et al.
April 17, 2012:1441–8 Peak Expiratory Flow Rate in AHFto be linked to improved clinical endpoints such as re-
hospitalization, mortality, or other established surrogates
such as BNP within clinical trials (26). However, in a recent
large randomized clinical trial enrolling patients with AHF,
those with early dyspnea relief had a greater weight loss and
a lower 30-day mortality than patients without dyspnea
relief as measured by a 7-point Likert scale (27). When
other surrogates such as pulmonary capillary wedge pressure
are measured, they are perceived to be of clinical value since
they can be re-assessed, standardized between patients,
sites, and trials, and provide objective evidence of improve-
ment. Given the disconnect between the measurement of
dyspnea as a symptom and clinical outcomes, we contend
that PEFR provides an improved approach for evaluating
respiratory function (25). Prior studies evaluating respira-
tory flow limitation have demonstrated a relationship be-
tween posture and airflow limitation consistent with our
overall results and may help explain the relationship be-
tween dyspnea, posture, pulmonary edema, and PEFR (28).
Further work should refine the role of the provocative
dyspnea test as a clinical trial endpoint (3) in the context of
objective measures of respiratory function including PEFR
and FEV1. In order for PEFR to be effectively used as a
surrogate in a large clinical trial, further efforts to define the
pathophysiology of peak flow limitation, measurement char-
acteristics of the instrument used (e.g., visual analogue
scale), and susceptibility of symptom measures to small
variations in positioning are required (29).
Study limitations. Our study has both limitations and
strengths. First, PEFR was used rather than FEV1. FEV1
has been shown to be an independent predictor of mortality
(30) and have a modest improvement in response to diuresis
(31). PEFR was selected because we sought to test a simple,
portable, reproducible, and inexpensive measurement that
could be applied in the acute setting across multiple sites
with minimal additional training. FEV1 and forced vital
capacity are also now available in portable units (albeit at a
greater expense), and both metrics are used clinically in
acute respiratory disease, with PEFR favored for asthma
and FEV1 for COPD. Although FEV1 and PEFR are
orrelated, PEFR underestimates the degree of respiratory
mpairment (32), and further studies should test both PEFR
nd FEV1 in the same cohort to determine the relative
erits of each measure. The baseline PEFR of 230 l/min in
ur study is lower than previously reported in a stable
utpatient HF population of 420 l/min, likely reflecting the
cute presentation of these patients with symptoms of
yspnea (33)—further PEFR data from a broad AHF
ohort with repeated measures would aid the generalizabil-
ty of our study. Second, our substudy was of modest size,
ut similar to the size of many phase II trials, and the largest
tudy of PEFR in patients with AHF. This further high-
ights the modest sample size required for demonstrating
hange in a clinical study with PEFR. Further exploration
f the dosing and timing of diuretics will need to be
xplored in the overall trial as well as in this cohort toxamine what effect, if any, is present. Third, the DI used in
SCEND-HF had few patients who worsened, and signif-
cant interpatient variability existed, requiring the creation
f a model highlighting moderate or marked improvement
rediction rather than using the entire scale. Further work
ill be required to understand the patient population who
eteriorated, and what, if any, subjective or objective mea-
urement should be used to predict this population.
onclusions
EFR is a useful objective measure that improves over the
rst 24 h of treatment for AHF. In this substudy of the
SCEND-HF trial, the improvement in PEFR was greater
ith nesiritide compared with placebo, and PEFR was
inked to the primary clinical outcome at 30 days. However,
he change in the DI was only modestly correlated with the
hange in PEFR. Additional validation in cohorts using
ultiple patient-reported symptom instruments and serial
easures of PEFR are required for the demonstration of
fficacy before use as an endpoint in clinical trials.
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